"Physostigmine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
| Descriptor ID |
D010830
|
| MeSH Number(s) |
D02.241.081.251.583.682 D03.132.436.545 D03.633.100.473.402.545
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Physostigmine".
Below are MeSH descriptors whose meaning is more specific than "Physostigmine".
This graph shows the total number of publications written about "Physostigmine" by people in this website by year, and whether "Physostigmine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Physostigmine" by people in Profiles.
-
Gutman DA, Hassid M, Jeanes Z, Redding AT, Romeo D. Prophylactic Physostigmine for Extreme and Refractory Adult Emergence Delirium, Aimed at Increasing Patient Safety and Reducing Health Care Workplace Violence: A Case Report. A A Pract. 2020 Apr; 14(6):e01205.
-
Yu QS, Reale M, Kamal MA, Holloway HW, Luo W, Sambamurti K, Ray B, Lahiri DK, Rogers JT, Greig NH. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, a-Synuclein synthesis, interleukin-1ß release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem. 2013; 12(2):117-28.
-
Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther. 2007 Jan; 320(1):386-96.
-
Utsuki T, Yu QS, Davidson D, Chen D, Holloway HW, Brossi A, Sambamurti K, Lahiri DK, Greig NH, Giordano T. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther. 2006 Aug; 318(2):855-62.
-
Alpert CC, Tobin DP, Dierdorf SF. Physostigmine for the acute treatment of restless legs syndrome. Anesth Analg. 2005 Sep; 101(3):726-727.
-
Göõz M, Tóth M, Vakkuri O, Göõz P, Smolka AJ, de Châtel R, Szalay KS. Endogenous ouabain-like factor (OLF) secretion is modulated by nicotinic mechanisms in rat adrenocortical cells. Life Sci. 2004 Mar 12; 74(17):2111-28.
-
Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7605-10.
-
Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
-
See RE, Chapman MA. Cholinergic modulation of oral activity in drug-naive and chronic haloperidol-treated rats. Pharmacol Biochem Behav. 1991 May; 39(1):49-54.
-
Riefler JF, Higerd TB. Characterization of intracellular esterase A from Bacillus subtilis. Biochim Biophys Acta. 1976 Mar 11; 429(1):191-7.